Joule Unlimited, Inc.

Joule Biotechnologies Introduces Revolutionary Process for Producing Renewable Transportation Fuels

Joule Biotechnologies Introduces Revolutionary Process for Producing Renewable Transportation Fuels

July 27, 2009

Two years into development, innovative startup enables path to energy independence; Unveils proprietary production system capable of supplying unlimited quantities of renewable fuel at costs competitive with fossil fuels

VisEn Medical, Inc.

VisEn Molecular Imaging Technology Enables Key Insights into Newly Discovered Biologic Pathway Published in Science

VisEn Molecular Imaging Technology Enables Key Insights into Newly Discovered Biologic Pathway Published in Science

July 30, 2009

BEDFORD, MA (July 30, 2009)-- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today that scientists reporting in the July 31 issue of SCIENCE have discovered a key disease-related biologic pathway using an integrated and innovative array of in vitro readouts and advanced in vivo imaging technologies. The newly reported biologic pathway relates to monocyte deployment from the spleen to inflammatory sites, including myocardial infarction.

Advanced Electron Beams, Inc

Advanced Electron Beams Raises $14.2 Million From GE, Flagship Ventures & Others for Market Penetration and Development of New Energy-Efficient Manufacturing Applications

Advanced Electron Beams Raises $14.2 Million From GE, Flagship Ventures & Others for Market Penetration and Development of New Energy-Efficient Manufacturing Applications

August 4, 2009

WILMINGTON, Mass. and STAMFORD, Conn. – August 4, 2009 – Advanced Electron Beams (AEB), whose compact electron beam technology helps traditional manufacturers become more environmentally sustainable while improving profitability, and GE Energy Financial Services, a unit of GE (NYSE: GE) announced today the close of a $14.2 million Series C financing, bringing AEB’s total amount raised to more than $50 million since October 2005.

Helicos BioSciences Corporation

Helicos BioSciences Announces the First Ever Single-Molecule View of Whole Human Genome

Helicos BioSciences Announces the First Ever Single-Molecule View of Whole Human Genome

August 10, 2009

Study Performed at Stanford University Published in Nature Biotechnology

Helicos BioSciences Corporation

Massachusetts General Hospital Cancer Center Takes Delivery of a Helicos(TM) Genetic Analysis System

Massachusetts General Hospital Cancer Center Takes Delivery of a Helicos(TM) Genetic Analysis System

August 13, 2009

Research team led by Dr. Daniel Haber to explore applicability of Helicos's technology to the molecular characterization of circulating tumor cells

CAMBRIDGE, Mass., Aug 13, 2009 (BUSINESS WIRE) -- Helicos BioSciences Corporation (NASDAQ: HLCS), a life science company focused on innovative genetic analysis technologies, today announced the placement of a Helicos(TM) Genetic Analysis System at the Massachusetts General Hospital (MGH) Cancer Center in the laboratory of Daniel Haber, MD, PhD.

Novomer, Inc.

Novomer Raises $14M Series B Financing

Novomer Raises $14M Series B Financing

August 18, 2009

Novomer Inc., a materials company pioneering a family of high-performance plastics, polymers and other chemicals from renewable feedstocks such as carbon dioxide, today announced that it has raised $14 million in a Series B funding.

Resolvyx Pharmaceuticals, Inc.

Resolvyx Announces Positive Data from Phase 2 Clinical Trial of the Resolvin RX-10045 in Patients with Dry Eye Syndrome

Resolvyx Announces Positive Data from Phase 2 Clinical Trial of the Resolvin RX-10045 in Patients with Dry Eye Syndrome

August 24, 2009

First Demonstration of Clinical Efficacy for Novel Class of Resolvin Therapeutics

VisEn Medical, Inc.

VisEn Launches New Annexin-Vivo 750 Fluorescence Molecular Imaging Agent

VisEn Launches New Annexin-Vivo 750 Fluorescence Molecular Imaging Agent

September 2, 2009

Enables Breakthrough in vivo Imaging Analysis of Established Apoptosis and Cell Death Biomarkers in Research and Drug Development

Quanterix Corporation

Dr. David Okrongly Appointed CEO of Quanterix Corporation

Dr. David Okrongly Appointed CEO of Quanterix Corporation

September 2, 2009

CAMBRIDGE, MA – September 2, 2009 – Quanterix Corporation, the leader in single molecule detection, announced today that David Okrongly, Ph.D. has been appointed Chief Executive Officer and a member of the company’s Board of Directors. Dr. Okrongly replaces co-founder and interim CEO, Nicholas Naclerio, Ph.D., who will continue serving as Chairman of the Board.

Helicos BioSciences Corporation

Helicos BioSciences Provides Q2 2009 Operating Highlights and Strategic Update

Helicos BioSciences Provides Q2 2009 Operating Highlights and Strategic Update

September 3, 2009

Achieves Significant Commercial and Technical Milestones

Engages Thomas Weisel Partners to Advise on Strategic Alternatives

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Helicos BioSciences Corporation (NASDAQ: HLCS) announced today its operating highlights for the quarter ended June 30, 2009 and other recent developments following the filing of its Quarterly Report on Form 10-Q for the period ended June 30, 2009.